Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO Registry

DAMINI JAWAHEER, JØRN OLSEN and MERETE LUND HETLAND
The Journal of Rheumatology January 2012, 39 (1) 46-53; DOI: https://doi.org/10.3899/jrheum.110548
DAMINI JAWAHEER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Djawaheer@chori.org
JØRN OLSEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MERETE LUND HETLAND
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    The observed proportions of (A) women and (B) men with good, moderate, or no EULAR responses, as well as sample sizes, are shown for each followup. A EULAR response could not be assessed for some patients who were missing DAS28 data at baseline; thus sample sizes are smaller than those shown in Figure 3.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Expected probabilities achieving a moderate/good EULAR response over time are shown, as an example, in men versus women in (A) early RA and (B) established RA, using mean baseline values of age, 28-joint Disease Activity Score (DAS28), and RA duration computed for early and established disease — based on the GEE model in Table 2.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The observed mean values of the 28-joint Disease Activity Score (DAS28) among men and women in early versus established RA and sample sizes at each followup are shown.

Tables

  • Figures
    • View popup
    Table 1.

    Summary of disease characteristics and medications at baseline by rheumatoid arthritis (RA) duration and sex. Results are mean ± SD or medians (interquartile range), unless otherwise indicated.

    RA Duration ≤ 2 YearsRA Duration > 2 Years
    CharacteristicMen, n = 148Women, n = 328pMen, n = 408Women, n = 1245p
    Age at diagnosis, yrs51.3 ± 13.250.1 ± 14.50.3744.6 ± 12.843.2 ± 15.00.07
    Disease duration, yrs1.23 ± 0.741.21 ± 0.700.7613.1 ± 8.913.8 ± 10.00.18
    Radiographic erosions, %51.949.10.6984.281.90.49
    RF seropositivity, %66.358.50.2085.481.30.18
    RA disease activity, %
      Mild6.32.65.74.8
      Moderate43.143.30.1640.738.00.43
      Severe50.754.153.657.2
    DAS285.1 ± 1.25.2 ± 1.10.455.2 ± 1.25.3 ± 1.10.26
    Tender joint count8 (4–16)10 (5–16)0.138 (4–14)9 (5–15)0.02
    Swollen joint count6 (3–11)6 (4–10)0.967 (4–11)7 (4–11)0.74
    CRP15 (7–45)11 (5–31)0.0318 (8–36)17 (8–35)0.11
    Patient global score59.7 ± 21.564.1 ± 23.10.0561.1 ± 21.762.3 ± 23.00.32
    Physician global score48.9 ± 21.747.9 ± 20.30.6547.1 ± 21.247.4 ± 21.20.79
    HAQ-DI1.0 ± 0.71.3 ± 0.70.00011.1 ± 0.81.5 ± 0.8< 0.00005
    Pain VAS55.1 ± 22.758.8 ± 23.70.1257.1 ± 21.958.1 ± 22.40.45
    Fatigue VAS59.3 ± 22.868.3 ± 21.20.3547.1 ± 22.350.3 ± 25.80.60
    Smoking history, %
      Current smoker42.934.30.3343.331.80.04
      Ever smoker71.465.70.5180.459.5< 0.0005
    Methotrexate, %7165.20.2265.965.80.96
    Prednisolone, %40.535.40.2852.940.9< 0.0005
    Anti-TNF therapy, %
      Infliximab42.64336.840.4
      Adalimumab31.131.70.9735.334.40.37
      Etanercept26.425.327.925.2
    • RF: rheumatoid factor; DAS28: 28-joint Disease Activity Score and C-reactive protein; CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire-Disability Index; VAS: visual analog scale; TNF: tumor necrosis factor.

    • View popup
    Table 2.

    Predictors of a moderate or good European League Against Rheumatism (EULAR) response in early and established rheumatoid arthritis (RA); generalized estimating equations (GEE) model.

    Outcome Variable: Moderate/Good EULAR ResponseRA ≤ 2 YearsRA > 2 Years
    Coefficient (95% CI)pCoefficient (95% CI)p
    Sex*0.93 (0.31, 1.55)0.0030.02 (−0.32, 0.36)0.90
    Followup, months0.08 (0.05, 0.12)< 0.00050.02 (0.009, 0.04)0.001
    Sex × followup−0.08 (−0.12, − 0.04)< 0.00050.003 (−0.01, 0.02)0.70
    Age**−0.01 (−0.02, 0.003)0.14−0.002 (−0.01, 0.006)0.62
    RA duration**0.18 (−0.14, 0.49)0.27−0.002 (−0.01, 0.008)0.70
    DAS28**0.46 (0.25, 0.67)< 0.00050.62 (0.52, 0.72)< 0.0005
    Anti-TNF therapy**0.05 (−0.22, 0.32)0.720.18 (0.05, 0.30)0.006
    Methotrexate**0.76 (0.33, 1.19)0.0010.25 (0.05, 0.46)0.01
    Prednisolone**−0.32 (−0.72, 0.08)0.11−0.31 (−0.50, −0.12)0.002
    Intercept−2.28 (−3.83, −0.72)0.004−2.36 (−3.15, —1.57)< 0.0005
    • Covariates adjusted for in the model are listed as independent variables.

    • ↵* The referent group for sex was male.

    • ↵** For these covariates, only baseline values were adjusted for in the GEE model. DAS28: 28-joint Disease Activity Score and C-reactive protein; TNF: tumor necrosis factor.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 1
1 Jan 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO Registry
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO Registry
DAMINI JAWAHEER, JØRN OLSEN, MERETE LUND HETLAND
The Journal of Rheumatology Jan 2012, 39 (1) 46-53; DOI: 10.3899/jrheum.110548

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO Registry
DAMINI JAWAHEER, JØRN OLSEN, MERETE LUND HETLAND
The Journal of Rheumatology Jan 2012, 39 (1) 46-53; DOI: 10.3899/jrheum.110548
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs
  • COVID-19 vaccine uptake among patients with systemic lupus erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
  • Association of M2 Macrophages, Th2, and B Cells With Pathomechanism in Microscopic Polyangiitis Complicated by Interstitial Lung Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire